{"id":211004,"date":"2017-02-24T19:49:50","date_gmt":"2017-02-25T00:49:50","guid":{"rendered":"http:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/uncategorized\/white-house-strategist-to-lead-uabs-personalized-medicine-institute-birmingham-times.php"},"modified":"2017-02-24T19:49:50","modified_gmt":"2017-02-25T00:49:50","slug":"white-house-strategist-to-lead-uabs-personalized-medicine-institute-birmingham-times","status":"publish","type":"post","link":"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/genetic-medicine\/white-house-strategist-to-lead-uabs-personalized-medicine-institute-birmingham-times.php","title":{"rendered":"White House strategist to lead UAB&#8217;s Personalized Medicine Institute &#8211; Birmingham Times"},"content":{"rendered":"<p><p>    ByKendra Carter  <\/p>\n<p>    UAB News  <\/p>\n<p>    Matthew Might, Ph.D., a renowned computer scientist and    strategic leader appointed to the White House Precision    Medicine Initiative by former President Barack Obama, has been    named the inaugural director of the Hugh Kaul Personalized    Medicine Institute at the University of Alabama at Birmingham    School of Medicine.  <\/p>\n<p>    Might comes to UAB from the University of Utah, where he is a    Presidential Scholar and an associate professor in both    computer science and pharmaceutical chemistry, and from Harvard    Medical School, where he is a visiting professor of biomedical    informatics. Mights research interests focus on the    intersection of computation and medicine to advance precision    medicine through personalized therapeutics.  <\/p>\n<p>    Precision medicine is an emerging practice of conducting    medicine that uses a comprehensive set of resources and    information  from an individuals family history and genetic    profile to lifestyle and environment  in order to guide    decisions for the prevention, diagnosis and treatment of    disease. It has attracted significant early attention for its    promise in treating rare diseases and cancers at their root    cause.  <\/p>\n<p>    The Hugh Kaul Personalized Medicine Institute, named by a gift    from the Hugh Kaul Foundation, was established in 2014. Might    will be the inaugural director of the institute. Nita Limdi,    Pharm.D., Ph.D., has served as interim director of the    institute since its creation.  <\/p>\n<p>    Dr. Might is a passionate scientist, and I believe that his    drive and strategic vision will make UAB a national leader in    precision medicine, said Selwyn M. Vickers, M.D., FACS, senior    vice president for Medicine and dean of the UAB School of    Medicine. He is an exceptional team builder, as evidenced by    what he has accomplished over the last nine years. He will be a    transformative presence for our patients and the academic    enterprise as we look to build on what UAB has already done    with undiagnosed diseases and expand those advances to deliver    effective, individualized care to patients with cancer and    common diseases.  <\/p>\n<p>    Mights shift into genetics and drug development was inspired    by his son Bertrand, who was diagnosed in 2012 as the first    case of NGLY1 deficiency, an ultra-rare genetic disorder. Might    then pioneered the use of social media and search engine    optimization to find other patients with the rare genetic    condition in a successful effort to advance scientific research    and drug development for the disease. He has since co-founded a    company that conducts personalized drug screens for genetic    epilepsy.  <\/p>\n<p>    Might was recruited in January 2015 by former President Barack    Obama to serve as an adviser to the then newly launched    Precision Medicine Initiative. He took on a formal role with    the Precision Medicine Initiative as a White House official in    the Executive Office of the President in March 2016.  <\/p>\n<p>    Im terrifically excited to be joining the UAB School of    Medicine, Might said. UAB leaders are making substantial    commitments to make precision medicine a reality for patients    in Alabama much sooner than it will be a reality anywhere else    in the country. Theres a unique constellation of resources    both within UAB, like the UAB Comprehensive Cancer Center,    Center for Genomic Medicine and Informatics Institute, and in    partnerships with Southern Research and HudsonAlpha that make    precision medicine realistic today.  <\/p>\n<p>    Might earned his bachelors, masters and doctoral degrees in    computer science from Georgia Tech before joining the    University of Utah in 2008.  <\/p>\n<p>    Mights first day at UAB will be July 1, 2017.  <\/p>\n<p><!-- Auto Generated --><\/p>\n<p>See more here:<\/p>\n<p><a target=\"_blank\" href=\"http:\/\/www.birminghamtimes.com\/2017\/02\/white-house-strategist-to-lead-uabs-personalized-medicine-institute\/\" title=\"White House strategist to lead UAB's Personalized Medicine Institute - Birmingham Times\">White House strategist to lead UAB's Personalized Medicine Institute - Birmingham Times<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"<p> ByKendra Carter UAB News Matthew Might, Ph.D., a renowned computer scientist and strategic leader appointed to the White House Precision Medicine Initiative by former President Barack Obama, has been named the inaugural director of the Hugh Kaul Personalized Medicine Institute at the University of Alabama at Birmingham School of Medicine. Might comes to UAB from the University of Utah, where he is a Presidential Scholar and an associate professor in both computer science and pharmaceutical chemistry, and from Harvard Medical School, where he is a visiting professor of biomedical informatics. Mights research interests focus on the intersection of computation and medicine to advance precision medicine through personalized therapeutics.  <a href=\"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/genetic-medicine\/white-house-strategist-to-lead-uabs-personalized-medicine-institute-birmingham-times.php\">Continue reading <span class=\"meta-nav\">&rarr;<\/span><\/a><\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"limit_modified_date":"","last_modified_date":"","_lmt_disableupdate":"","_lmt_disable":"","footnotes":""},"categories":[5],"tags":[],"class_list":["post-211004","post","type-post","status-publish","format-standard","hentry","category-genetic-medicine"],"modified_by":null,"_links":{"self":[{"href":"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/wp-json\/wp\/v2\/posts\/211004"}],"collection":[{"href":"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/wp-json\/wp\/v2\/comments?post=211004"}],"version-history":[{"count":0,"href":"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/wp-json\/wp\/v2\/posts\/211004\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/wp-json\/wp\/v2\/media?parent=211004"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/wp-json\/wp\/v2\/categories?post=211004"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/wp-json\/wp\/v2\/tags?post=211004"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}